Clinical features | Renal endpoints reached | P value | |
---|---|---|---|
Yes | No | ||
Number of patients | 30 | 245 | |
Mean age (years) | 42 ± 22 | 33 ± 16 | 0.052 |
Gender (Male/Female) | 21/9 | 122/123 | 0.036 |
Extrarenal manifestation | |||
Skin (n, %) | 30 (100%) | 245 (100%) | |
Gastrointestinal tract (n, %) | 4 (13.3%) | 62 (24.3%) | 0.147 |
Joints (n, %) | 1 (3.3%) | 45 (18.4%) | 0.068 |
MAP (mmHg) | 100 ± 9 | 94 ± 11 | 0.012 |
Scr (μmol/L) | 103.0 (74.8217.8) | 63.0 (53.0,78.0) | <0.001 |
eGFR (ml/min/1.73m2) | 67.4 (30.1, 115.4) | 121.2 (92.6, 140.1) | <0.001 |
Proteinuria(g/24 h) | 2.7 (1.0, 5.0) | 1.12 (0.6, 2.7) | <0.001 |
Immunosuppressant therapy (n, %) | 24 (80.0%) | 176 (71.8%) | 0.343 |
Steroids only(n) | 6 | 93 | 0.019 |
Steroids + IVC/MMF(n) | 18 | 83 | |
ACEI/ARB | 12 (40.0%) | 83 (33.9%) | 0.51 |